Label update notes depression drug's impact on processing speed

3 May 2018

The US label for Trintellix (vortioxetine) now includes data showing improvement in processing speed among patients taking the depression drug.

This measure is seen as an important aspect of cognitive function observed in some patients with major depressive disorder (MDD), so proof of the improvement with Trintellix is a potential step forward in a condition that is now the leading cause of disability worldwide.

The clinical trials section of the US label now includes data from the FOCUS and CONNECT trials, showing the positive effect on processing speed with Trintellix, a drug developed by the Danish CNS specialist Lundbeck (LUND: CO) that is marketed in the USA by the Japanese pharma major Takeda (TYO: 4502).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK